Q-omics provides the consensus-scored EPCAM-DT profile across patient tissues and cancer cell-line models. EPCAM-DT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, EPCAM-DT is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, EPCAM-DT RNA expression shows 16,975 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where EPCAM-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPCAM-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPCAM-DT survival associations across molecular data types. EPCAM-DT RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPCAM-DT RNA expression–survival associations across cancer types. High EPCAM-DT expression shows unfavorable associations in ACC, but favorable associations in HNSC, BLCA, KIRP, LGG and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for EPCAM-DT RNA expression.
This table summarizes EPCAM-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for EPCAM-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPCAM-DT shows lower tumor expression in COAD, KICH, READ, LUSC and BRCA and higher tumor expression in LIHC. The COAD box plot shows higher EPCAM-DT RNA expression in normal versus tumor tissue (log2 FC = −1.520, t-test p < 0.001).
This table shows molecular features associated with EPCAM-DT in patient tissues and cancer cell lines. In patient samples, EPCAM-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
